SCHEMBL27242011

SCHEMBL27242011

CCOC(=O)c1cn2c(C)cc(C)nc2n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.55
KDM4E B2RXH2 7/20 0.50
ALDH1A1 P00352 6/20 0.50
HPGD P15428 4/20 0.50
RAB9A P51151 2/20 0.49
NPC1 O15118 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
POLB P06746 1/20 0.47
DPP4 P27487 1/20 0.47
DPP8 Q6V1X1 1/20 0.47
DPP9 Q86TI2 1/20 0.47
MAPK1 P28482 1/20 0.45
CYP1A2 P05177 1/20 0.45
ALOX15 P16050 1/20 0.43
GABRA2 P47869 1/20 0.43
GABRB2 P47870 1/20 0.43
RCE1 Q9Y256 1/20 0.43
HSD17B10 Q99714 1/20 0.42
MEN1 O00255 1/20 0.42
THRB P10828 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5439236 0.86 GAA (0.52) GAAKDM4EALDH1A1HPGDPOLB
SCHEMBL24378550 0.80 DPP4 (0.53) GAAKDM4EALDH1A1HPGDPOLB
SCHEMBL27242010 0.80 KDM4E (0.55) KDM4EALDH1A1HPGDRAB9ANPC1
SCHEMBL13732825 0.77 GAA (0.58) GAAKDM4EALDH1A1HPGDRAB9A
SCHEMBL23530849 0.77 GAA (0.66) GAAKDM4EALDH1A1HPGDRAB9A
SCHEMBL24401545 0.75 GAA (0.47) GAAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL26079081 0.74 GAA (0.56) GAAKDM4EALDH1A1HPGDRAB9A
SCHEMBL19438624 0.73 KDM4E (0.69) GAAKDM4EALDH1A1HPGDRAB9A
SCHEMBL2930501 0.72 GAA (0.56) GAAKDM4EALDH1A1HPGDRAB9A
SCHEMBL10469595 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12012410-B2 Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy REBORNA BIOSCIENCES, INC. (JP) 2024-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12012410-B2 Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy SMN1; SMN2, HDAC5, PUM1 GAA 290/4885KDM4E 1818/4885ALDH1A1 1801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.